Viveve Medical, Inc. · OTC:VIVE
Viveve Medical — Investor Presentation (April 2015)
20 slides from Viveve Medical's investor presentation, Apr 21, 2015
Slide 1: Corporate Presentation
viveve. Awoman’s sexual satisfaction is fundamental Talking about it is monumental Corporate Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement viveve All statements in this presentation that are not based on historical fact are “forward looking statements”. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were bas
Slide 3: Company Highlights
Company Highlights Significant Market Opportunities Safe & Effective Procedure Backed by Proprietary Technology Well Positioned for Rapid Growth Experienced Management Team Strong Support From Sophisticated Advisors and Investors viveve Total accessible global market opportunity of $78 over the next
Slide 4: Company Overview
Company Overview viveve ° Viveve is a women’s health company focused on the commercialization of a revolutionary, non-surgical, non-ablative medical device to remodel collagen and restore vaginal tissue © Viveve System uses patented, reverse-thermal gradient radio frequency (RF) technology to tighte
Slide 5: Significant Unmet Need
Significant Unmet Need viveve Vaginal Laxity is a significant concern for women e Vaginal childbirth overstretches the vaginal introitus (opening) In a survey of 524 US OB/GYNs, vaginal v Feeling of “Looseness” laxity is the #1 reported post-delivery Y Diminished sensation during sexual physical cha
Slide 6: Global Post-Partum Market Opportunity
Global Post-Partum Market Opportunity”) Women Between 25-45 Years Old: Cumulative Market Potential 41MM x Canada $150M Women With Household Income > $70k: ~ 33% = 13.5MM Hong Kong S5OM Japan $700M Europe $1,500M Total Existing MKT $2.48 Latin America $750M Viveve's $600 Consumable oe) Seu) Target Ma
Slide 7: US Regulatory Pathway
US Regulatory Pathway viveve CE Mark and Health Canada Indication: The Viveve System is indicated for the treatment of the vaginal introitus after childbirth to improve sexual function © FDA in-person meeting confirmed that to obtain same indication will require: v de novo 510K pathway v Patient rep
Slide 8: The Viveve Solution
The Viveve Solution viveve The Viveve® System utilizes a globally patented, reverse-thermal gradient technology based on RF energy that is clinically proven System is composed of two main components: @ Physician operated table-top device @® Single-use consumable treatment tip
Slide 9: The Viveve Procedure
The Viveve Procedure viveve Only clinically proven & effective, non-surgical procedure for vaginal laxity Treatment tip delivers pulses to the tissue Each pulse lasts approximately 8 seconds Total procedures consists of “105 pulses Total procedure lasts only 30 minutes
Slide 10: Customer Benefits
Customer Benefits viveve Phy: in Benefits Patient Benefits © Technically simple procedure with low risk 30 minute in-office / outpatient procedure * Self-pay / cash procedure avoids e No anesthesia required reimbursement challenges 4 a 8 e Non-ablative and non-surgical * Potential new source of sign
Slide 11: Mechanism of Action
Mechanism of Action viveve 1. Application of low-dose, non-ablative RF energy . Activation of fibroblasts which produce new collagen fibers in the vaginal tissue . Initiation of tissue response with collagen remodeling . Collagen restoration process takes place over time, usually within 30-90 days a
Slide 12: Successful Clinical Study Results
Successful Clinical Study Results viveve Subjects: 38 sheep * Subjects: 24 healthy women _* Subjects: 30 healthy women © Objective: Utilize RF therapy * Objective: Determine the * Objective: Determine the to stimulate tissue response, human patient response to human patient response to titrate dosin
Slide 13: Positive Laxity Outcomes — US & Japan
SSS SS... S__= Positive Laxity Outcomes — US & Japan viveve The Viveve Treatment restored vaginal tightness to pre-childbirth levels goo] 53 us sTUDY 40 JAPAN STUDY & 480g a 40 Z 2008 2 Be a Bao paaest fer i = 3 30 Boo | & ‘J a ae 26 pono. H be po001 a | tL Bo 2 10 Priorto Baseline Month Month3--Mon
Slide 14: VIVEVE Study
VIVEVE | Study viveve Viveve Treatment of the Vaginal Introitus to EValuate Efficacy * Randomized, blinded and sham controlled OUS study * Enrolling113 patients at up to 10 clinical sites in Europe and Canada * Primary Endpoint: Proportion of patients reporting no vaginal laxity at 6 months versus t
Slide 15: Commercial Launch Strategy
Commercial Launch Strategy viveve ¢ Select countries with large and demonstrative market opportunities e Establish strong distribution network in all countries — direct in US e Build brand and market awareness using clinical data and KOL acceptance Canada @) Russe e @ a Europe: ® Japan ©) ws East @
Slide 16: Proprietary Intellectual Property
Proprietary Intellectual Property viveve Licenses * Viveve has royalty-free, perpetual, fully paid-up rights to pivotal patents, including their foreign and other derivatives from: v Ed Knowlton (inventor of RF patents for tissue tightening assigned to Thermage, Inc."), now Valeant Pharmaceuticals I
Slide 17: Experienced Management Team
Experienced Management Team viveve Patricia Scheller - CEO & Director : < .° + Over 25 years in medical device and consumer product companies Golunonafohien SomaLogic + Joined Viveve in May 2012 ‘ + Responsible for launching the PALMAZ-SCHATZ® balloon-expandable stent, DADE BEHRING prESCIENT MEDICAL
Slide 18: Sophisticated Advisors and Investors
Sophisticated Advisors and Investors viveve Board of Directors Board Brigitte Smith - Chairwoman a + Co-founder and Managing Partner, GBS Ventures* GBS + Over 20 years of experience in ventures capital + Previously a strategic management consultant at Bain & Company Mark Colella* + Principal, SAM Ve
Slide 19: Financing History and Current Ownership
Financing History and Current Ownership viveve * Since inception, Viveve has raised approximately $33 million in equity capital and has $4 million in debt outstanding = $27 million raised in three pre-PLC merger equity/debt financings = $6 million in the PIPE offering in connection with the PLC merg
Slide 20: Investment Highlights
Investment Highlights viveve Significant Market Opportunities Safe & Effective Procedure Backed by Proprietary Technology Strong Support From Sophisticated Advisors and Investors ViVeve. Well Positioned for Rapid Growth Experienced Management Team